ScripThe positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp
ScripSome three years after COVID-19 kickstarted a massive adoption of digital technology and shift to remote monitoring in clinical development, technology continues to effect seismic changes in the trial
ScripMerck KGaA has continued its run of dealmaking in the oncology field by licensing out its tumor-targeting interleukin-12 fusion protein M924 to PDS Biotechnology Corporation . The German group will
ScripGenexine Inc. ’s first-in-class DNA therapeutic vaccine candidate for HPV-related cancers, GX-188E, has impressed in a challenging cohort of cervical cancer patients in combination with Merck & Co.,